|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan DS, Agarwal R and Kaye SB: Mechanisms
of transcoelomic metastasis in ovarian cancer. Lancet Oncol.
7:925–934. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
di Re F, Baiocchi G, Fontanelli R, Grosso
G, Cobellis L, Raspagliesi F and di Re E: Systematic pelvic and
paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic
significance of node metastases. Gynecol Oncol. 62:360–365. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pereira A, Magrina JF, Rey V, Cortes M and
Magtibay PM: Pelvic and aortic lymph node metastasis in epithelial
ovarian cancer. Gynecol Oncol. 105:604–608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kleppe M, Wang T, Van Gorp T, Slangen BF,
Kruse AJ and Kruitwagen RF: Lymph node metastasis in stages I and
II ovarian cancer: a review. Gynecol Oncol. 123:610–614. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ayhan A, Gultekin M, Dursun P, Dogan NU,
Aksan G, Guven S, Velipasaoglu M and Yuce K: Metastatic lymph node
number in epithelial ovarian carcinoma: Does it have any clinical
significance? Gynecol Oncol. 108:428–432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
du Bois A, Reuss A, Harter P,
Pujade-Lauraine E, Ray-Coquard I and Pfisterer J;
Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe
Ovarialkarzinom; Groupe d’Investigateurs Nationaux pour l’Etude des
Cancers Ovariens: Potential role of lymphadenectomy in advanced
ovarian cancer: A combined exploratory analysis of three
prospectively randomized phase III multicenter trials. J Clin
Oncol. 28:1733–1739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hacker NF, Valmadre S and Robertson G:
Management of retroperitoneal lymph nodes in advanced ovarian
cancer. Int J Gynecol Cancer. 18(Suppl 1): 7–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harter P, Gnauert K, Hils R, Lehmann TG,
Fisseler-Eckhoff A, Traut A and du Bois A: Pattern and clinical
predictors of lymph node metastases in epithelial ovarian cancer.
Int J Gynecol Cancer. 17:1238–1244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
House CD, Hernandez L and Annunziata CM:
Recent technological advances in using mouse models to study
ovarian cancer. Front Oncol. 4:262014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ruan HY, Li DR, Li L, Guan X and Zhang W:
Establishment of human ovarian carcinoma cell lines with
directional highly lymphatic metastasis and study of their
biological characteristics. Zhonghua Fu Chan Ke Za Zhi. 42:482–486.
2007.In Chinese. PubMed/NCBI
|
|
12
|
Shenhua X, Lijuan Q, Hanzhou N, Xinghao N,
Chihong Z, Gu Z, Weifang D and Yongliang G: Establishment of a
highly metastatic human ovarian cancer cell line (HO-8910PM) and
its characterization. J Exp Clin Cancer Res. 18:233–239.
1999.PubMed/NCBI
|
|
13
|
Servais EL, Colovos C, Bograd AJ, White J,
Sadelain M and Adusumilli PS: Animal models and molecular imaging
tools to investigate lymph node metastases. J Mol Med (Berl).
89:753–769. 2011. View Article : Google Scholar
|
|
14
|
Tamada Y, Aoki D, Nozawa S and Irimura T:
Model for paraaortic lymph node metastasis produced by orthotopic
implantation of ovarian carcinoma cells in athymic nude mice. Eur J
Cancer. 40:158–163. 2004. View Article : Google Scholar
|
|
15
|
Kang Y, Chen CM and Xu CJ: Secretion of
oestrogen from murine-induced pluripotent stem cells co-cultured
with ovarian granulosa cells in vitro. Cell Bio Int. 35:871–874.
2011. View Article : Google Scholar
|
|
16
|
Sood AK, Coffin JE, Schneider GB, Fletcher
MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD and Hendrix
MJ: Biological significance of focal adhesion kinase in ovarian
cancer: role in migration and invasion. Am J Pathol. 165:1087–1095.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sood AK, Bhatty R, Kamat AA, Landen CN,
Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S and Cole SW:
Stress hormone-mediated invasion of ovarian cancer cells. Clin
Cancer Res. 12:369–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Spannuth WA, Mangala LS, Stone RL, et al:
Converging evidence for efficacy from parallel EphB4-targeted
approaches in ovarian carcinoma. Mol Cancer Ther. 9:2377–2388.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khan IU, Shahid A, Ahmad F, Dar UK, Ahmad
M and Javed M: Studying the biological feasibility of
[99mTc(CO)3]-dextran-cystein
e-cysteine-mannose as a potential molecular radiopharmaceutical for
sentinel node detection. Ann Nucl Med. 28:248–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kang Y, Hu W, Ivan C, et al: Role of focal
adhesion kinase in regulating YB-1-mediated paclitaxel resistance
in ovarian cancer. J Natl Cancer Inst. 105:1485–1495. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Van den Broeck W, Derore A and Simoens P:
Anatomy and nomenclature of murine lymph nodes: Descriptive study
and nomenclatory standardization in BALB/cAnNCrl mice. J Immunol
Methods. 312:12–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Onda T, Yoshikawa H, Yokota H, Yasugi T
and Taketani Y: Assessment of metastases to aortic and pelvic lymph
nodes in epithelial ovarian carcinoma. A proposal for essential
sites for lymph node biopsy. Cancer. 78:803–808. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Benedet JL, Bender H, Jones H III, Ngan HY
and Pecorelli S: FIGO staging classifications and clinical practice
guidelines in the management of gynecologic cancers. FIGO Committee
on Gynecologic Oncology. Int J Gynaecol Obstet. 70:209–262. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim HS, Ju W, Jee BC, Kim YB, Park NH,
Song YS, Kim SC, Kang SB and Kim JW: Systematic lymphadenectomy for
survival in epithelial ovarian cancer: a meta-analysis. Int J
Gynecol Cancer. 20:520–528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rygaard J and Povlsen CO:
Heterotransplantation of a human malignant tumour to ‘Nude’ mice.
Acta Pathol Microbiol Scand. 77:758–760. 1969. View Article : Google Scholar
|
|
26
|
Shaw TJ, Senterman MK, Dawson K, Crane CA
and Vanderhyden BC: Characterization of intraperitoneal, orthotopic
and metastatic xenograft models of human ovarian cancer. Mol Ther.
10:1032–1042. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanks SK and Polte TR: Signaling through
focal adhesion kinase. BioEssays. 19:137–145. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao J and Guan JL: Signal transduction by
focal adhesion kinase in cancer. Cancer Metastasis Rev. 28:35–49.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanks SK, Ryzhova L, Shin NY and Brábek J:
Focal adhesion kinase signaling activities and their implications
in the control of cell survival and motility. Front Biosci.
8:d982–996. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schlaepfer DD, Hauck CR and Sieg DJ:
Signaling through focal adhesion kinase. Prog Biophys Mol Biol.
71:435–478. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McLean GW, Carragher NO, Avizienyte E,
Evans J, Brunton VG and Frame MC: The role of focal-adhesion kinase
in cancer-a new therapeutic opportunity. Nat Rev Cancer. 5:505–515.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Judson PL, He X, Cance WG and Van Le L:
Overexpression of focal adhesion kinase, a protein tyrosine kinase,
in ovarian carcinoma. Cancer. 86:1551–1556. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gabriel B, Mildenberger S, Weisser CW,
Metzger E, Gitsch G, Schüle R and Müller JM: Focal adhesion kinase
interacts with the transcriptional coactivator FHL2 and both are
overexpressed in epithelial ovarian cancer. Anticancer Res.
24:921–927. 2004.PubMed/NCBI
|
|
34
|
Grisaru-Granovsky S, Salah Z, Maoz M,
Pruss D, Beller U and Bar-Shavit R: Differential expression of
protease activated receptor 1 (Par1) and pY397FAK in benign and
malignant human ovarian tissue samples. Int J Cancer. 113:372–378.
2005. View Article : Google Scholar
|
|
35
|
Shibata K, Kikkawa F, Nawa A, Thant AA,
Naruse K, Mizutani S and Hamaguchi M: Both focal adhesion kinase
and c-Ras are required for the enhanced matrix metalloproteinase 9
secretion by fibronectin in ovarian cancer cells. Cancer Res.
58:900–903. 1998.PubMed/NCBI
|
|
36
|
Wang X, Urvalek AM, Liu J and Zhao J:
Activation of KLF8 transcription by focal adhesion kinase in human
ovarian epithelial and cancer cells. J Biol Chem. 283:13934–13942.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
van Nimwegen MJ, Verkoeijen S, van Buren
L, Burg D and van de Water B: Requirement for focal adhesion kinase
in the early phase of mammary adenocarcinoma lung metastasis
formation. Cancer Res. 65:4698–4706. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mitra SK, Lim ST, Chi A and Schlaepfer DD:
Intrinsic focal adhesion kinase activity controls orthotopic breast
carcinoma metastasis via the regulation of urokinase plasminogen
activator expression in a syngeneic tumor model. Oncogene.
25:4429–4440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Halder J, Lin YG, Merritt WM, et al:
Therapeutic efficacy of a novel focal adhesion kinase inhibitor
TAE226 in ovarian carcinoma. Cancer Res. 67:10976–10983. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Infante JR, Camidge DR, Mileshkin LR, et
al: Safety, pharma-cokinetic and pharmacodynamic phaseI
dose-escalation trial of PF-, an inhibitor of focal adhesion
kinase, in advanced solid tumors. J Clin Oncol. 30:1527–1533. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun H, Pisle S, Gardner ER and Figg WD:
Bioluminescent imaging study: FAK inhibitor, PF-562,271,
preclinical study in PC3M-luc-C6 local implant and metastasis
xenograft models. Cancer Biol Ther. 10:38–43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ji HF, Pang D, Fu SB, Jin Y, Yao L, Qi JP
and Bai J: Overexpression of focal adhesion kinase correlates with
increased lymph node metastasis and poor prognosis in
non-small-cell lung cancer. J Cancer Res Clin Oncol. 139:429–435.
2013. View Article : Google Scholar
|
|
43
|
de Vicente JC, Rosado P,
Lequerica-Fernández P, Allonca E, Villallaín L and
Hernández-Vallejo G: Focal adhesion kinase overexpression:
Correlation with lymph node metastasis and shorter survival in oral
squamous cell carcinoma. Head Neck. 35:826–830. 2013. View Article : Google Scholar
|
|
44
|
Cai HX, Yang LC, Song XH, Liu ZR, Chen YB
and Dong GK: Expression of paxillin and FAK mRNA and the related
clinical significance in esophageal carcinoma. Mol Med Rep.
5:469–472. 2012.
|
|
45
|
Park JH, Lee BL, Yoon J, Kim J, Kim MA,
Yang HK and Kim WH: Focal adhesion kinase (FAK) gene amplification
and its clinical implications in gastric cancer. Hum Pathol.
41:1664–1673. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jiang H, Liu L, Ye J, Liu H, Xing S and Wu
Y: Focal adhesion kinase serves as a marker of cervical lymph node
metastasis and is a potential therapeutic target in tongue cancer.
J Cancer Res Clin Oncol. 136:1295–1302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gabriel B, Hasenburg A, Waizenegger M,
Orlowska-Volk M, Stickeler E and zur Hausen A: Expression of focal
adhesion kinase in patients with endometrial cancer: a
clinicopathologic study. Int J Gynecol Cancer. 19:1221–1225. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rodrigo JP, Dominguez F, Suárez V, Canel
M, Secades P and Chiara MD: Focal adhesion kinase and E-cadherin as
markers for nodal metastasis in laryngeal cancer. Arch Otolaryngol
Head Neck Surg. 133:145–150. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miyazaki T, Kato H, Nakajima M, Sohda M,
Fukai Y, Masuda N, Manda R, Fukuchi M, Tsukada K and Kuwano H: FAK
overexpression is correlated with tumour invasiveness and lymph
node metastasis in oesophageal squamous cell carcinoma. Br J
Cancer. 89:140–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
